Published in:
Open Access
01-12-2017 | Research
Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states
Authors:
Behiye Özcan, Pieter J. M. Leenen, Patric J. D. Delhanty, Lucy Y. Baldéon-Rojas, Sebastian J. Neggers, Aart Jan van der Lely
Published in:
Diabetology & Metabolic Syndrome
|
Issue 1/2017
Login to get access
Abstract
Background
Type 2 diabetes (T2D) is associated with reduced numbers and impaired function of circulating angiogenic cells (CAC) which contributes to the progression of atherosclerosis and microvascular disease. Previous studies suggest that short-term infusion of unacylated ghrelin (UAG) normalizes CAC number in patients with T2D. To determine dose-dependent effects of short-term infusion of UAG in T2D patients using a cross-over model, and of long-term infusion of UAG in obese mice, on differentiation of monocyte progenitors into CAC.
Methods
Eight overweight T2D patients were infused overnight with 3 and 10 µg/kg/h of UAG in a double-blind, placebo-controlled cross-over study. To assess the effects of long-term UAG treatment, obese mice were infused with UAG for 4 weeks. Monocyte progenitors were assessed for their ability to differentiate into CAC in vitro.
Results
In T2D patients, UAG treatment caused a reduction in differentiation of CAC, dependent on UAG dose and differentiation method. However, mice treated with UAG showed a significant increase in differentiation of bone marrow progenitors into CAC.
Conclusion
UAG causes a minor suppressive effect on CAC development after short-term treatment in humans, but experiments in mice suggest that long-term treatment has beneficial effects on CAC formation.
The Netherlands Trial Register: TC=2487